1. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer;Kabbinavar;J Clin Oncol,2003
2. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004
3. Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups;Fyfe;Proc Am Soc Clin Oncol,2004
4. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIb/IV NSCLC;DeVore;Proc Am Soc Clin Oncol,2000
5. Scappaticci F, Fehrenbacher L, Cartwright, T, et al. Analysis of wound healing and bleeding post-surgery in metastatic colorectal cancer patients treated with bevacizumab. In: Proceedings of the 2004 Gastrointestinal Cancers Symposium; January 22-24, 2004; San Francisco, CA. Abstract #235.